Burzynski Research Institute, Inc. (BZYR)
USD 0.05
(-1.63%)
USD 0.05
(-1.63%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 | 2310.00 USD | 19.44% |
| 2023 | 1934.00 USD | -58.51% |
| 2022 | 4661.00 USD | 387.55% |
| 2021 | 956.00 USD | -95.18% |
| 2020 | 19.85 Thousand USD | -10.46% |
| 2019 | 22.17 Thousand USD | -23.36% |
| 2018 | 28.92 Thousand USD | 169.58% |
| 2017 | 10.73 Thousand USD | 169.15% |
| 2016 | 3987.00 USD | 9.29% |
| 2015 | 3648.00 USD | 59.93% |
| 2014 | 2281.00 USD | -41.93% |
| 2013 | 3928.00 USD | -81.04% |
| 2012 | 20.71 Thousand USD | -4.07% |
| 2011 | 21.59 Thousand USD | -6.01% |
| 2010 | 22.97 Thousand USD | 39.63% |
| 2009 | 16.45 Thousand USD | 59.6% |
| 2008 | 10.31 Thousand USD | -20.23% |
| 2007 | 12.92 Thousand USD | -39.65% |
| 2006 | 21.41 Thousand USD | -67.48% |
| 2005 | 65.85 Thousand USD | -11.14% |
| 2004 | 74.11 Thousand USD | 12.69% |
| 2003 | 65.76 Thousand USD | -28.39% |
| 2002 | 91.83 Thousand USD | -19.23% |
| 2001 | 113.7 Thousand USD | -41.57% |
| 2000 | 194.59 Thousand USD | -42.55% |
| 1999 | 338.7 Thousand USD | -22.68% |
| 1998 | 438.06 Thousand USD | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q4 | 2310.00 USD | 128.04% |
| 2024 FY | 2310.00 USD | 19.44% |
| 2024 Q2 | 1797.00 USD | 111.91% |
| 2024 Q1 | 848.00 USD | -56.15% |
| 2024 Q3 | 1013.00 USD | -43.63% |
| 2023 Q3 | 1792.00 USD | 7.56% |
| 2023 FY | 1934.00 USD | -58.51% |
| 2023 Q4 | 1934.00 USD | 7.92% |
| 2023 Q1 | 5466.00 USD | 17.27% |
| 2023 Q2 | 1666.00 USD | -69.52% |
| 2022 Q3 | 6739.00 USD | 266.25% |
| 2022 Q4 | 4661.00 USD | -30.84% |
| 2022 Q1 | 2009.00 USD | 110.15% |
| 2022 Q2 | 1840.00 USD | -8.41% |
| 2022 FY | 4661.00 USD | 387.55% |
| 2021 Q2 | 2962.00 USD | -68.16% |
| 2021 FY | 956.00 USD | -95.18% |
| 2021 Q3 | 2142.00 USD | -27.68% |
| 2021 Q1 | 9302.00 USD | -53.15% |
| 2021 Q4 | 956.00 USD | -55.37% |
| 2020 Q3 | 32.55 Thousand USD | -29.37% |
| 2020 FY | 19.85 Thousand USD | -10.46% |
| 2020 Q1 | 12.85 Thousand USD | -42.0% |
| 2020 Q2 | 46.09 Thousand USD | 258.45% |
| 2020 Q4 | 19.85 Thousand USD | -39.02% |
| 2019 Q3 | 33.66 Thousand USD | -25.69% |
| 2019 Q2 | 45.3 Thousand USD | 167.83% |
| 2019 Q1 | 16.91 Thousand USD | -41.53% |
| 2019 Q4 | 22.17 Thousand USD | -34.14% |
| 2019 FY | 22.17 Thousand USD | -23.36% |
| 2018 Q4 | 28.92 Thousand USD | -19.84% |
| 2018 FY | 28.92 Thousand USD | 169.58% |
| 2018 Q1 | 382.00 USD | -96.44% |
| 2018 Q2 | 504.00 USD | 31.94% |
| 2018 Q3 | 36.08 Thousand USD | 7060.12% |
| 2017 Q3 | 1053.00 USD | 37.47% |
| 2017 FY | 10.73 Thousand USD | 169.15% |
| 2017 Q4 | 10.73 Thousand USD | 919.09% |
| 2017 Q2 | 766.00 USD | -44.17% |
| 2017 Q1 | 1372.00 USD | -65.59% |
| 2016 Q1 | 1677.00 USD | -54.03% |
| 2016 Q2 | 1528.00 USD | -8.88% |
| 2016 Q3 | 1445.00 USD | -5.43% |
| 2016 Q4 | 3987.00 USD | 175.92% |
| 2016 FY | 3987.00 USD | 9.29% |
| 2015 Q2 | 7519.00 USD | 99.71% |
| 2015 Q1 | 3765.00 USD | 65.06% |
| 2015 FY | 3648.00 USD | 59.93% |
| 2015 Q3 | 3535.00 USD | -52.99% |
| 2015 Q4 | 3648.00 USD | 3.2% |
| 2014 Q2 | 3240.00 USD | -15.73% |
| 2014 Q3 | 2307.00 USD | -28.8% |
| 2014 Q1 | 3845.00 USD | -2.11% |
| 2014 Q4 | 2281.00 USD | -1.13% |
| 2014 FY | 2281.00 USD | -41.93% |
| 2013 FY | 3928.00 USD | -81.04% |
| 2013 Q4 | 3928.00 USD | -29.12% |
| 2013 Q2 | 17.2 Thousand USD | -5.46% |
| 2013 Q1 | 18.19 Thousand USD | -12.16% |
| 2013 Q3 | 5542.00 USD | -67.79% |
| 2012 FY | 20.71 Thousand USD | -4.07% |
| 2012 Q4 | 20.71 Thousand USD | 5.03% |
| 2012 Q3 | 19.72 Thousand USD | -24.84% |
| 2012 Q2 | 26.24 Thousand USD | 31.41% |
| 2012 Q1 | 19.96 Thousand USD | -7.53% |
| 2011 FY | 21.59 Thousand USD | -6.01% |
| 2011 Q4 | 21.59 Thousand USD | 0.88% |
| 2011 Q3 | 21.4 Thousand USD | 2.23% |
| 2011 Q2 | 20.94 Thousand USD | -16.12% |
| 2011 Q1 | 24.96 Thousand USD | 8.65% |
| 2010 Q3 | 19.9 Thousand USD | 5.96% |
| 2010 Q1 | 21.12 Thousand USD | 28.36% |
| 2010 Q2 | 18.78 Thousand USD | -11.08% |
| 2010 Q4 | 22.97 Thousand USD | 15.46% |
| 2010 FY | 22.97 Thousand USD | 39.63% |
| 2009 Q2 | 18.54 Thousand USD | 66.59% |
| 2009 Q3 | 14.66 Thousand USD | -20.88% |
| 2009 Q4 | 16.45 Thousand USD | 12.18% |
| 2009 FY | 16.45 Thousand USD | 59.6% |
| 2009 Q1 | 11.13 Thousand USD | 7.94% |
| 2008 Q3 | 9014.00 USD | -30.16% |
| 2008 Q4 | 10.31 Thousand USD | 14.39% |
| 2008 Q1 | 30.96 Thousand USD | 139.53% |
| 2008 Q2 | 12.9 Thousand USD | -58.32% |
| 2008 FY | 10.31 Thousand USD | -20.23% |
| 2007 FY | 12.92 Thousand USD | -39.65% |
| 2007 Q4 | 12.92 Thousand USD | -33.65% |
| 2007 Q3 | 19.48 Thousand USD | 2.05% |
| 2007 Q2 | 19.09 Thousand USD | -5.22% |
| 2007 Q1 | 20.14 Thousand USD | -5.95% |
| 2006 Q1 | 61.27 Thousand USD | -6.96% |
| 2006 FY | 21.41 Thousand USD | -67.48% |
| 2006 Q4 | 21.41 Thousand USD | -77.44% |
| 2006 Q3 | 94.94 Thousand USD | 67.16% |
| 2006 Q2 | 56.79 Thousand USD | -7.31% |
| 2005 Q4 | 65.85 Thousand USD | -15.12% |
| 2005 Q2 | 76.87 Thousand USD | 11.85% |
| 2005 Q1 | 68.72 Thousand USD | -7.27% |
| 2005 Q3 | 77.58 Thousand USD | 0.93% |
| 2005 FY | 65.85 Thousand USD | -11.14% |
| 2004 Q3 | 65.34 Thousand USD | -20.06% |
| 2004 Q2 | 81.74 Thousand USD | -4.9% |
| 2004 Q4 | 74.11 Thousand USD | 13.42% |
| 2004 FY | 74.11 Thousand USD | 12.69% |
| 2004 Q1 | 85.94 Thousand USD | 30.69% |
| 2003 FY | 65.76 Thousand USD | -28.39% |
| 2003 Q3 | 86.92 Thousand USD | 26.09% |
| 2003 Q4 | 65.76 Thousand USD | -24.34% |
| 2003 Q2 | 68.93 Thousand USD | -0.65% |
| 2003 Q1 | 69.38 Thousand USD | -24.45% |
| 2002 FY | 91.83 Thousand USD | -19.23% |
| 2002 Q3 | 78.49 Thousand USD | -19.83% |
| 2002 Q1 | 108.19 Thousand USD | -4.85% |
| 2002 Q2 | 97.9 Thousand USD | -9.5% |
| 2002 Q4 | 91.83 Thousand USD | 16.99% |
| 2001 Q2 | 148.24 Thousand USD | -12.19% |
| 2001 Q4 | 113.7 Thousand USD | -25.15% |
| 2001 FY | 113.7 Thousand USD | -41.57% |
| 2001 Q1 | 168.82 Thousand USD | -13.24% |
| 2001 Q3 | 151.9 Thousand USD | 2.47% |
| 2000 FY | 194.59 Thousand USD | -42.55% |
| 2000 Q4 | 194.59 Thousand USD | 0.0% |
| 1999 FY | 338.7 Thousand USD | -22.68% |
| 1998 FY | 438.06 Thousand USD | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Arch Therapeutics, Inc. | 1.95 Million USD | 99.882% |
| Evofem Biosciences, Inc. | 10.55 Million USD | 99.978% |
| Nascent Biotech, Inc. | 552.12 Thousand USD | 99.582% |
| Rebus Holdings, Inc. | 5000.00 USD | 53.8% |
| Santhera Pharmaceuticals Holding AG | 130.21 Million USD | 99.998% |
| Qrons Inc. | 420.00 USD | -450.0% |
| Adynxx, Inc. | - USD | -Infinity% |
| Neon Bloom, Inc. | 770.64 Thousand USD | 99.7% |
| Northwest Biotherapeutics, Inc. | 27.94 Million USD | 99.992% |
| ProtoKinetix, Incorporated | 480.55 Thousand USD | 99.519% |
| Skye Bioscience, Inc. | 11.94 Million USD | 99.981% |
| Eiger BioPharmaceuticals, Inc. | 38.84 Million USD | 99.994% |
| Nanobac Pharmaceuticals, Incorporated | 7.21 Million USD | 99.968% |
| Institute of Biomedical Research Corp. | 76.35 Thousand USD | 96.975% |
| SQZ Biotechnologies Company | 107.18 Million USD | 99.998% |
| Intellipharmaceutics International Inc. | 1.43 Million USD | 99.839% |
| Propanc Biopharma, Inc. | 72.36 Thousand USD | 96.808% |
| Mesoblast Limited | 667.9 Million USD | 100.0% |
| Marizyme, Inc. | 22.01 Million USD | 99.99% |
| Genus plc | 1.02 Billion USD | 100.0% |
| VioQuest Pharmaceuticals, Inc. | 1.35 Million USD | 99.83% |
| Pharming Group N.V. | 462.85 Million USD | 100.0% |
| Therapeutic Solutions International, Inc. | 3.31 Million USD | 99.93% |
| CNBX Pharmaceuticals Inc. | 499.03 Thousand USD | 99.537% |
| Nymox Pharmaceutical Corporation | 627 Thousand USD | 99.632% |
| ContraFect Corporation | 20.67 Million USD | 99.989% |
| PsyBio Therapeutics Corp. | 390.36 Thousand USD | 99.408% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 382.17 Thousand USD | 99.396% |
| IMV Inc. | 31.33 Million USD | 99.993% |
| AXIM Biotechnologies, Inc. | 4.14 Million USD | 99.944% |
| MultiCell Technologies, Inc. | 126.22 USD | -1730.138% |
| ONE Bio Corp. | 70.08 Million USD | 99.997% |
| Accustem Sciences Inc. | 939.68 Thousand USD | 99.754% |
| RVL Pharmaceuticals plc | 128.51 Million USD | 99.998% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 431.71 Thousand USD | 99.465% |
| Q BioMed Inc. | 3.51 Million USD | 99.934% |
| Emmaus Life Sciences, Inc. | 35.17 Million USD | 99.993% |
| Mosaic ImmunoEngineering Inc. | 261.27 Thousand USD | 99.116% |
| Biomind Labs Inc. | 73.81 Thousand USD | 96.871% |
| American Oriental Bioengineering, Inc. | 446.3 Million USD | 99.999% |
| Provectus Biopharmaceuticals, Inc. | 1.44 Million USD | 99.841% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 30.01 Million USD | 99.992% |
| GlobeStar Therapeutics Corporation | - USD | -Infinity% |
| THC Farmaceuticals, Inc. | 2.74 Million USD | 99.916% |
| Acro Biomedical Co., Ltd. | 687.48 Thousand USD | 99.664% |
| Curative Biotechnology, Inc. | 2.6 Million USD | 99.911% |
| GB Sciences, Inc. | 103.44 Thousand USD | 97.767% |
| Alpha Cognition Inc. | 2.45 Million USD | 99.906% |
| HST Global, Inc. | 1526.00 USD | -51.376% |
| CSL Limited | 38.02 Billion USD | 100.0% |
| Wesana Health Holdings Inc. | 987.96 Thousand USD | 99.766% |
| Halberd Corporation | 10.13 Thousand USD | 77.199% |
| Enzolytics Inc. | 361.7 Million USD | 99.999% |
| Agentix Corp. | 261.39 Thousand USD | 99.116% |
| Resverlogix Corp. | 8.11 Million USD | 99.972% |
| Nuo Therapeutics, Inc. | 1.87 Million USD | 99.877% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 4.54 Billion USD | 100.0% |
| Enzon Pharmaceuticals, Inc. | 47.7 Million USD | 99.995% |
| Endonovo Therapeutics, Inc. | 639.65 Thousand USD | 99.639% |
| RespireRx Pharmaceuticals Inc. | 22.78 Thousand USD | 89.86% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 8.94 Million USD | 99.974% |
| AVAX Technologies, Inc. | 7.37 Million USD | 99.969% |
| Zenith Capital Corp. | 7410.00 USD | 68.826% |
| Genscript Biotech Corporation | 3.38 Billion USD | 100.0% |
| Ember Therapeutics, Inc. | 184.00 USD | -1155.435% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 321.8 Thousand USD | 99.282% |
| WPD Pharmaceuticals Inc. | 261.36 Thousand USD | 99.116% |
| Cotinga Pharmaceuticals Inc. | 927.96 Thousand USD | 99.751% |
| Kadimastem Ltd | 2.3 Million USD | 99.9% |
| Helix BioMedix, Inc. | 3.02 Million USD | 99.924% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 52.7 Million USD | 99.996% |
| BioStem Technologies, Inc. | 14.56 Million USD | 99.984% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 57.09 Thousand USD | 95.954% |
| LadRx Corporation | 2.3 Million USD | 99.9% |
| Cell Source, Inc. | 195.17 Thousand USD | 98.816% |
| Regen BioPharma, Inc. | 353.61 Thousand USD | 99.347% |
| Regen BioPharma, Inc. | 353.61 Thousand USD | 99.347% |
| NovAccess Global Inc. | 62.24 Thousand USD | 96.289% |
| Affymax, Inc. | 7.44 Million USD | 99.969% |
| Itoco Inc. | 1.4 Million USD | 99.835% |
| Rasna Therapeutics, Inc. | 95.65 Thousand USD | 97.585% |
| Pathfinder Cell Therapy, Inc. | 106 Thousand USD | 97.821% |
| Mobile Lads Corp. | 52.00 USD | -4342.308% |
| CytoDyn Inc. | 11.13 Million USD | 99.979% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 142.97 Thousand USD | 98.384% |
| NanoSphere Health Sciences Inc. | 17.88 Thousand USD | 87.081% |
| Alseres Pharmaceuticals, Inc. | 385.47 Thousand USD | 99.401% |
| SYBLEU INC | 330.46 Thousand USD | 99.301% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 409.42 Thousand USD | 99.436% |
| International Stem Cell Corporation | 5.39 Million USD | 99.957% |
| Bioxytran, Inc. | 137.63 Thousand USD | 98.322% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 15 Million USD | 99.985% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | - USD | -Infinity% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 16.57 Million USD | 99.986% |
| Adhera Therapeutics, Inc. | 79 Thousand USD | 97.076% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 864.67 Thousand USD | 99.733% |
| Innovation Pharmaceuticals Inc. | 7.51 Million USD | 99.969% |
| Neutra Corp. | 2851.00 USD | 18.976% |
| Windtree Therapeutics, Inc. | 32.4 Million USD | 99.993% |
| PureTech Health plc | 693.97 Million USD | 100.0% |
| Coeptis Therapeutics, Inc. | 8.07 Million USD | 99.971% |
| IXICO plc | 15.84 Million USD | 99.985% |
| IntelGenx Technologies Corp. | 8.28 Million USD | 99.972% |
| Gelesis Holdings, Inc. | 103.32 Million USD | 99.998% |
| CSL Limited | 38.02 Billion USD | 100.0% |
| Cellectis S.A. | 333.99 Million USD | 99.999% |